Atopic dermatitis is characterized by skin barrier abnormalities and immune dysregulation with increased T H 2 signaling playing a central role. Investigations of allergic contact dermatitis suggest that certain allergens may also activate particular T cell signatures such as T H 2-dominant responses to fragrance and rubber. We present a case series of patients with allergic contact dermatitis who were successfully treated with dupilumab, a biologic developed for atopic dermatitis that dampens T H 2 signaling. In our cohort of three patients, two had extensive allergic contact dermatitis on their torso and extremities primarily due to textile and rubber allergens.
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The third was a hairdresser with severe hand dermatitis due to occupational allergens. Two of the three patients had no history of atopic dermatitis during childhood. Each patient experienced at least 90% improvement in body surface area involvement and continues to maintain their clinical response on dupilumab (range 6-13 months). Our hypothesis that dupilumab suppressed contact allergic reactions is supported by the identification of clinically relevant contact allergens on patch testing, acute onset and/or worsening of dermatitis in adulthood, and absence of childhood atopic dermatitis in two cases. Further, larger investigations to understand which factors affect responses of allergic contact dermatitis to dupilumab are warranted. also indicate that specific contact allergens may activate particular T-cell signatures such as T H 2-dominant responses to fragrance and rubber (Dhingra et al., 2014) . Therefore, for certain allergens eliciting ACD, immunomechanisms may more closely overlap those of AD than for other allergens. We present a case series of patients with ACD who were successfully treated with dupilumab, a biologic developed for AD that dampens T H 2 signaling (Simpson et al., 2016) .
| MATERIALS AND METHODS
Patch testing was performed using allergens (Chemotechnique Diagnostics, Malmö, Sweden) placed in Finn Chambers ® (Smart Practice, Phoenix, Arizona) on Scanpore ® tape. Allergens were adhered to the skin for 48 hr. A first read was performed at the time of patch removal followed by a delayed read 1-3 days later. Reactions were graded using the International Contact Dermatitis Research Group (ICDRG) classification. Given that each patient's severe ACD was insufficiently improved with allergen avoidance or other standard therapies, dupilumab was initiated administered as a 600 mg loading dose followed by 300 mg every 2 weeks thereafter.
| RESULTS
Our three patients were women, 20, 52, and 53 years-of-age ( were tested to our standard, cosmetic/preservative/adhesive, fragrance, rubber, textile, and bakery series. Patient 3 was also tested to our hair and shoe series.
a These allergen categories were considered the most clinically relevant ones in each case.
b
These allergens were positive on prior patch testing, and were not retested in our clinic. Prior reports of severe, recalcitrant hand dermatitis responding to dupilumab, either noted no relevant allergens on patch testing (Zirwas, 2018) or no improvement with allergen avoidance (Oosterhaven, Romeijn, & Schuttelaar, 2018 
